Basic and Translational Research at the Renal Division
The Division of Renal Diseases and Hypertension at the University of 麻豆传媒高清 has a longstanding international reputation for excellence in research. The Division faculty are well funded with total annual funding in excess of $12 million, including NIH, VA, DoD, corporate and foundation sources, placing the Division in the top ten in the country for research funding. The Division has been at the forefront of advances in nephrology, specifically in the areas related to acute kidney injury, polycystic kidney disease, hypertension, fluid and electrolyte disorders, and glomerulonephritis.
The Division holds an NIH T32 Training grant and has so for over 44 years. Our faculty and fellows continue our research mission in basic science, translational and clinical research. We are committed to training and cultivating the next generation of researchers in nephrology.
The Division of Renal Diseases and Hypertension has world-renowned researchers in basic and translational science. There are extensive opportunities for training in basic science research within the Division. Our basic science research efforts focus on acute kidney injury, chronic kidney disease, diabetic kidney disease, polycystic kidney disease, glomerular disease, vascular biology, cell biology, vascular calcification, transplantation, hypertension, obesity and kidney fibrosis.
The research is performed in state of the art facilities in approximately 18,000 square feet of laboratory space in the Division of Renal Diseases and Hypertension. The renal labs are equipped for cell culture, protein purification, molecular biology, animal models of renal disease and imaging. Each of the faculty has operating research laboratories. Funding from the NIH, VA, American Heart Association, Polycystic Kidney Disease Foundation and private contributions supports these endeavors.
The Division of Renal Diseases and Hypertension also has world-renowned clinical research, with extensive opportunities for training. Our clinical research efforts focus on chronic kidney disease, polycystic kidney disease, glomerular disease, hypertension, and obesity.
The research is performed in a state of the art research clinic including 4 exam rooms, a waiting room, phlebotomy station, and laboratory space utilized by the Division of Renal Diseases and Hypertension. There is a state-of-the art Clinical and Vascular Physiology laboratory. Staff includes full-time registered nurses, a biostatistician, skilled laboratory technicians, administrative personnel, and information systems personnel, all of whom help investigators by facilitating the day-to-day research process. Funding from the NIH, Department of Defense, VA, Polycystic Kidney Disease Foundation, and private contributions supports these endeavors.
April 6: Michelle Josephson, MD from the University of Chicago will deliver the annual Laurence Chan Lectureship
April 13: Alp Ikizler, MD from Vanderbilt University will deliver the annual Wahlstrom Lectureship
May 4: Deidra Crews, MD from John Hopkins University will deliver the annual Collins Lectureship
May 22: Vishal Patel, MD from UT Southwestern will deliver the annual Schrier Lectureship
Laboratory Sciences Professional (Intermediate - Senior Level), Requisition 34668
Post-Doctoral Fellow, Requisition 34830
Hopp K, Catenacci VA, Dwivedi N, Kline TL, Wang W, You Z, Nguyen DT, Bing K, Poudyal B, Johnson GC, Jackman MR, Miller M, Steele CN, Serkova NJ, MacLean PS, Nemenoff RA, Gitomer B, Chonchol M, Nowak KL.
Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease. iScience. 2022;25(1):103697. Epub 2022/01/22. doi: 10.1016/j.isci.2021.103697. PubMed PMID: 35059607; PMCID: PMC8760407.
Montford JR, Bauer C, Rahkola J, Reisz JA, Floyd D, Hopp K, Soranno DE, Klawitter J, Weiser-Evans MCM, Nemenoff R, Faubel S, Furgeson SB.
15-Lipoxygenase worsens renal fibrosis, inflammation, and metabolism in a murine model of ureteral obstruction. Am J Physiol Renal Physiol. 2022;322(1):F105-F19. Epub 2021/12/07. doi: 10.1152/ajprenal.00214.2021. PubMed PMID: 34866403; PMCID: PMC8742724.
Soranno DE, Baker P, 2nd, Kirkbride-Romeo L, Wennersten SA, Ding K, Keith B, Cavasin MA, Altmann C, Bagchi RA, Haefner KR, Montford J, Gist KM, Vergnes L, Reue K, He Z, Elajaili H, Okamura K, Nozik E, McKinsey TA, Faubel S.
Female and male mice have differential longterm cardiorenal outcomes following a matched degree of ischemia-reperfusion acute kidney injury. Scientific reports. 2022;12(1):643. Epub 2022/01/14. doi: 10.1038/s41598-021-04701-x. PubMed PMID: 35022484; PMCID: PMC8755805.
Trachtman H, Laskowski J, Lee C, Renner B, Feemster A, Parikh S, Panzer SE, Zhong W, Cravedi P, Cantarelli C, Kulik L, You Z, Satchell S, Rovin B, Liu F, Kalled SL, Holers VM, Jalal D, Thurman JM.
Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome. Am J Physiol Renal Physiol. 2021;321(4):F505-F16. Epub 2021/08/31. doi: 10.1152/ajprenal.00041.2021. PubMed PMID: 34459222; PMCID: PMC8560405.
CU Anschutz
Research Complex II
12700 East 19th Avenue
Aurora, CO 80045
303.724.4852